reports
TELA Bio to Announce First Quarter 2025 Financial Results
TELA Bio to Announce First Quarter 2025 Financial Results MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors...
Absci to Report Business Updates and First Quarter 2025 Financial and ...
Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025 VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter 2025 after market close on Tuesday, May 13, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and ...
Sono-Tek to Present at the Planet MicroCap Showcase: VEGAS in partners...
Sono-Tek to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025 MILTON, N.Y., April 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SOTK), the leading developer and manufacturer of ultrasonic coating systems, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 1:30 PM ET. Dr. Christopher L. Coccio, Executive Chairman and Steve Harshbarger, CEO & President of Sono-Tek will be hosting the presentation...
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® P...
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the market MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: TELA), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction solutions, today announced the U.S. launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, the only tissue-based device reinforced with polymer suture embroidery specifically engineered for plastic...
Absci to Participate in Upcoming Investor Conferences
Absci to Participate in Upcoming Investor Conferences VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences. H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceFireside chat on Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time 24th Annual Needham Virtual Healthcare ConferenceFireside chat on Tuesday, April 8 at 3...
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for O...
Absci Reports Business Updates and Fourth Quarter and Full Year 2024 F...
Absci Reports Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results Unveiled updates across proprietary pipeline and demonstrated new breakthroughs by AI platform at 2024 R&D Day Entered into collaboration with AMD, including $20 million strategic investment in Absci Achieved 2024 outlook for drug creation partnerships through collaborations with Owkin, Twist Bioscience, Invetx, and Memorial Sloan Kettering Cancer Center Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. a...
Sono-Tek Corporation Promotes Chris Cichetti to Chief Operating Office...
Sono-Tek Corporation Promotes Chris Cichetti to Chief Operating Officer MILTON, N.Y., March 05, 2025 (GLOBE NEWSWIRE) -- Sono-Tek Corporation (NASDAQ: SOTK), a leading developer and manufacturer of ultrasonic coating systems, is pleased to announce the promotion of Chris Cichetti to the position of Chief Operating Officer (COO). Chris Cichetti joined Sono-Tek in 2005 as an Electrical Engineer and has since held several key roles within the Company, including Senior Application Engineer and Manager of the Application Engineering Department. Most recently, he served as Vice President of Sa...
Absci to Report Business Updates and Fourth Quarter and Full Year 2024...
Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025 VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2024 after market close on Tuesday, March 18, 2025. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its bus...
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on March 3, 2025, the company granted a non-statutory stock option to purchase an aggregate of 162,800 shares of its common stock to one newly-hired non-executive employee. The inducement grant was previously approved by the Compensation Committee of Absci’s Board of Directors pursuant to Absci’s 2023 Inducement Plan (the “Inducement Plan”), and is bei...
Absci to Participate in the KeyBanc Capital Markets Healthcare Forum
Absci to Participate in the KeyBanc Capital Markets Healthcare Forum VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming virtual KeyBanc Capital Markets Healthcare Forum. Absci management is scheduled to participate in a fireside chat on Wednesday, March 19th at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.ab...
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Resul...
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 20, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Fourth Quarter Earnings Conference ...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 7,200 shares of its common stock to thirteen newly-hired employees, with a grant date of February 19, 2025 (the "Grant Date"). The restricted stock units were grante...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
S&P 500 and Nasdaq 100 Breaking Out We are seeing signs that this 2+ month consolidation in the S&P 500 and Nasdaq 100 (QQQ) is ready to break out to the upside. Part of that is the obvious; both the SPX and QQQ are breaking out to marginal new highs. The other part that has kept us bullish this whole time is that market dynamics have remained risk-on, which we have discussed on a weekly basis. Bottom line: our outlook remains bullish as long as the S&P 500 remains above 5770-5850. Our recommen...
PAG PENSKE AUTOMOTIVE GROUP INC
KMX CARMAX INC.
LYG.. LLOYDS BANKING GROUP PLC ADS
LOPE GRAND CANYON EDUCATION INC.
LINC LINCOLN EDUCATIONAL SERVICES
LAD LITHIA MOTORS INC. CLASS A
GPI GROUP 1 AUTOMOTIVE INC.
BFAM BRIGHT HORIZONS FAMILY SOLUTIONS INC.
BCS BARCLAYS PLC ADS
APEI AMERICAN PUBLIC EDUCATION
AN AUTONATION INC.
SAH SONIC AUTOMOTIVE INC. CLASS A
LAUR LAUREATE EDUCATION INC. CLASS A
ATGE ADTALEM GLOBAL EDUCATION INC.
STRA STRATEGIC EDUCATION INC.
AFYA AFYA
PRDO PERDOCEO EDUCATION CORP
DUOL DUOLINGO INC
UTI MULTI UNITS LU - AMUNDI STOXX EUROPE 600 UTILITIES UCITS ETF
Adtalem Global Education Inc: 1 director
A director at Adtalem Global Education Inc sold 4,812 shares at 103.257USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Absci to Participate in the TD Cowen 45th Annual Health Care Conferenc...
Absci to Participate in the TD Cowen 45th Annual Health Care Conference VANCOUVER, Wash. and NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming TD Cowen 45th Annual Health Care Conference in Boston, MA. Absci management is scheduled to participate in a fireside chat on Monday, March 3rd at 3:10 p.m. Eastern Time (12:10 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: inve...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
S&P 500 Holding Above Prior Breakout Level Yet Again As discussed throughout the first half of January, we continue to believe that tariffs will mostly be used as a negotiation tactic, and much like Trump's prior presidency, will be much less impactful than feared. We reiterated this in yesterday's pre-market ETF Pathfinder, also noting "we anticipate the Canada/Mexico tariffs to be resolved relatively quickly, and therefore we view the latest pullback as a buying opportunity." Sure enough, bot...
NTRA NATERA
MMSI MERIT MEDICAL SYSTEMS INC.
MDT MEDTRONIC PLC
LINC LINCOLN EDUCATIONAL SERVICES
FMS FRESENIUS MEDICAL CARE AG & CO. KGAA ADS
BMY BRISTOL-MYERS SQUIBB COMPANY
APEI AMERICAN PUBLIC EDUCATION
BSX. BELO SUN MINING CORP.
PEN PANORO ENERGY ASA
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
LAUR LAUREATE EDUCATION INC. CLASS A
ATGE ADTALEM GLOBAL EDUCATION INC.
DGS. DIVIDEND GROWTH SPLIT
GH GUARDANT HEALTH
STRA STRATEGIC EDUCATION INC.
LRN STRIDE INC
LH LABCORP HOLDINGS INC
GSK GSK PLC
PROD PROSVETNO DELO AD ORD
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
VIAV VIAVI SOLUTIONS INC
ROLL RBC BEARINGS INCORPORATED
NRIM NORTHRIM BANCORP INC.
KEYS KEYSIGHT TECHNOLOGIES INC
JBT JOHN BEAN TECHNOLOGIES CORPORATION
GLW CORNING INC
EMN EASTMAN CHEMICAL COMPANY
CIEN CIENA CORPORATION
CAMT CAMTEK LTD.
BMI BADGER METER INC.
BEN FRANKLIN RESOURCES INC.
TATT TAT TECHNOLOGIES LTD.
INTT INTEST CORP.
PLSE PULSE BIOSCIENCES
LCUT LIFETIME BRANDS
ISSC INNOVATIVE SOLUTIONS & SUPPORT INC.
SRTS SENSUS HEALTHCARE
FTG111 FLATEXDEGIRO AG
CVCO CAVCO INDUSTRIES INC.
ATGE ADTALEM GLOBAL EDUCATION INC.
JHG JANUS HENDERSON GROUP PLC
BKR BAKER HUGHES COMPANY CLASS A
INS INTELLIGENT SYSTEMS CORP.
AVGO BROADCOM INC.
CSPI CSP INC.
TSSI TSS INC
INMB INMUNE BIO
TARS TARSUS PHARMACEUTICALS
HIMS HIMS AND HERS HEALTH INC (A)
GTLB GITLAB INC
VERV VERVE THERAPEUTICS INC
LNSR LENSAR INC
TEAM ATLASSIAN CORPORATION
BKSY BLACKSKY TECHNOLOGY INC
BBCN39 JPMORGAN BETABUILDERS CANADA BDR
VATE INNOVATE CORP
MNPR MONOPAR THERAPEUTICS INC.
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Jan. 24, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 4,000 shares of its common stock to seven newly-hired employees, with a grant date of January 21, 2025 (the "Grant Date"). The restricted stock units were granted pu...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Local Tops for 10-Year Yield, DXY, and WTI Crude Oil Our outlook remains bullish, and since late-December we have been suggesting to use the pullback as a buying opportunity. Our most recent and highest conviction "buy the dip" call came last week (1/14/25 Compass) amid all the major indexes testing key supports (S&P 500, Nasdaq 100, DJI, S&P Mid Caps, VXF, Russell 2000, ARKK, and SMH), bullish breadth divergences, and other ongoing risk-on signals. Those dip buys are finally paying off, with a...
PAG PENSKE AUTOMOTIVE GROUP INC
KMX CARMAX INC.
LINC LINCOLN EDUCATIONAL SERVICES
LAD LITHIA MOTORS INC. CLASS A
JBL JABIL INC.
GPI GROUP 1 AUTOMOTIVE INC.
FAN FABRINET
APEI AMERICAN PUBLIC EDUCATION
AN AUTONATION INC.
FLEXN FLEX LTD.
SAH SONIC AUTOMOTIVE INC. CLASS A
UTI UNIVERSAL TECHNICAL INSTITUTE INC.
LAUR LAUREATE EDUCATION INC. CLASS A
ATGE ADTALEM GLOBAL EDUCATION INC.
PRDO PERDOCEO EDUCATION CORP
LRN STRIDE INC
CLS CELESTICA INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.